BET bromodomain inhibition synergizes with PARP inhibitor in epithelial ovarian cancer

PARP inhibition is known to be an effective clinical strategy in BRCA-mutant cancers, but PARP inhibition has not been applied to BRCA-proficient tumors. Here we show synergy of BET bromodomain inhibition with PARP inhibition in BRCA-proficient ovarian cancers due to mitotic catastrophe. Treatment o...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cell Rep
Asıl Yazarlar: Karakashev, Sergey, Zhu, Hengrui, Yokoyama, Yuhki, Zhao, Bo, Fatkhutdinov, Nail, Kossenkov, Andrew V., Wilson, Andrew J., Simpkins, Fiona, Speicher, David, Khabele, Dineo, Bitler, Benjamin G., Zhang, Rugang
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2017
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5745042/
https://ncbi.nlm.nih.gov/pubmed/29262321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2017.11.095
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller